Intuitive Surgical, Inc. (NASDAQ:ISRG) Stake Lifted by Covea Finance

Covea Finance raised its position in Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 40.2% in the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 86,348 shares of the medical equipment provider's stock after buying an additional 24,748 shares during the period. Intuitive Surgical comprises 1.9% of Covea Finance's investment portfolio, making the stock its 14th biggest position. Covea Finance's holdings in Intuitive Surgical were worth $42,766,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of ISRG. Onefund LLC grew its stake in Intuitive Surgical by 1.9% during the 4th quarter. Onefund LLC now owns 947 shares of the medical equipment provider's stock worth $494,000 after purchasing an additional 18 shares in the last quarter. AlphaCore Capital LLC raised its position in Intuitive Surgical by 4.2% in the 4th quarter. AlphaCore Capital LLC now owns 451 shares of the medical equipment provider's stock valued at $235,000 after purchasing an additional 18 shares in the last quarter. Parkside Financial Bank & Trust boosted its stake in shares of Intuitive Surgical by 2.6% in the 4th quarter. Parkside Financial Bank & Trust now owns 747 shares of the medical equipment provider's stock valued at $390,000 after buying an additional 19 shares during the period. Accredited Investors Inc. grew its position in shares of Intuitive Surgical by 1.9% during the fourth quarter. Accredited Investors Inc. now owns 1,040 shares of the medical equipment provider's stock worth $543,000 after buying an additional 19 shares in the last quarter. Finally, Second Line Capital LLC grew its position in shares of Intuitive Surgical by 3.4% during the fourth quarter. Second Line Capital LLC now owns 578 shares of the medical equipment provider's stock worth $302,000 after buying an additional 19 shares in the last quarter. Institutional investors and hedge funds own 83.64% of the company's stock.

Intuitive Surgical Trading Down 0.0%

ISRG stock traded down $0.13 during mid-day trading on Friday, hitting $509.36. 2,827,555 shares of the company were exchanged, compared to its average volume of 1,677,653. The firm has a fifty day simple moving average of $528.03 and a 200 day simple moving average of $537.38. The company has a market capitalization of $182.56 billion, a PE ratio of 74.69, a price-to-earnings-growth ratio of 5.40 and a beta of 1.67. Intuitive Surgical, Inc. has a twelve month low of $413.82 and a twelve month high of $616.00.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last posted its quarterly earnings results on Tuesday, April 22nd. The medical equipment provider reported $1.81 EPS for the quarter, topping analysts' consensus estimates of $1.71 by $0.10. The business had revenue of $2.25 billion during the quarter, compared to the consensus estimate of $2.19 billion. Intuitive Surgical had a return on equity of 14.43% and a net margin of 28.41%. During the same period last year, the firm earned $1.50 earnings per share. As a group, sell-side analysts anticipate that Intuitive Surgical, Inc. will post 6.43 earnings per share for the current year.

Insiders Place Their Bets

In related news, SVP Mark Brosius sold 216 shares of the company's stock in a transaction that occurred on Friday, June 6th. The stock was sold at an average price of $563.11, for a total transaction of $121,631.76. Following the sale, the senior vice president now directly owns 907 shares of the company's stock, valued at approximately $510,740.77. This represents a 19.23% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Jami K. Nachtsheim sold 2,400 shares of Intuitive Surgical stock in a transaction on Thursday, May 1st. The stock was sold at an average price of $520.00, for a total transaction of $1,248,000.00. Following the completion of the transaction, the director now directly owns 6,371 shares of the company's stock, valued at approximately $3,312,920. This represents a 27.36% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 4,998 shares of company stock valued at $2,611,577 in the last quarter. Insiders own 0.70% of the company's stock.

Analysts Set New Price Targets

ISRG has been the topic of several analyst reports. Erste Group Bank raised shares of Intuitive Surgical from a "hold" rating to a "buy" rating in a report on Thursday, June 5th. Piper Sandler dropped their price objective on shares of Intuitive Surgical from $670.00 to $575.00 and set an "overweight" rating on the stock in a research report on Wednesday, April 23rd. BTIG Research set a $560.00 price objective on shares of Intuitive Surgical and gave the stock a "buy" rating in a research report on Monday, April 14th. Deutsche Bank Aktiengesellschaft downgraded shares of Intuitive Surgical from a "hold" rating to a "sell" rating and lowered their target price for the stock from $515.00 to $440.00 in a research note on Monday, June 9th. Finally, Evercore ISI dropped their target price on Intuitive Surgical from $510.00 to $470.00 and set an "in-line" rating on the stock in a report on Wednesday, April 23rd. One analyst has rated the stock with a sell rating, four have assigned a hold rating and fifteen have assigned a buy rating to the company. According to data from MarketBeat.com, Intuitive Surgical has an average rating of "Moderate Buy" and a consensus price target of $588.95.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.